Association Between Bleeding Time and Platelet Adherence to Artery Subendothelium

K S Sakariassen; P A Bolhuis; Margaretha Blombäck; L Thorell; Birger Blombäck; J J Sixma

doi:10.1055/s-0038-1661159

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1984; 52(02): 144-147
DOI: 10.1055/s-0038-1661159

Original Article

Schattauer GmbH Stuttgart

Association Between Bleeding Time and Platelet Adherence to Artery Subendothelium

Authors

K S Sakariassen

¹The Department of Haematology, University Hospital Utrecht, The Netherlands
P A Bolhuis

¹The Department of Haematology, University Hospital Utrecht, The Netherlands
Margaretha Blombäck

³The Department of Blood Coagulation Disorders, Karolinska Sjukhuset, Stockholm, Sweden
L Thorell

²The Department of Blood Coagulation Research, Karolinska Instituted Stockholm, Sweden
Birger Blombäck

²The Department of Blood Coagulation Research, Karolinska Instituted Stockholm, Sweden
J J Sixma

¹The Department of Haematology, University Hospital Utrecht, The Netherlands

Abstract

PDF Download

Summary

The efficacy of five different factor VUI-von Willebrand factor (FVIII-VWF) preparations in mediating adherence of blood platelets to damaged vessel walls was tested in an annular perfusion chamber utilizing human arteries and reconstituted blood.

FVIII-VWF-purified by Sepharose CL-4B chromatography and von Willebrand factor prepared from this preparation by dissociation with 0.25 M CaCl₂ followed by Sepharose CL-6B chromatography were equally effective in mediating platelet adherence as FVIII-VWF in cryoprecipitate and in plasma from normal subjects. A commercial concentrate of FVIII-VWF (Hemofil, Hyland) used for the treatment of haemophiliacs did not mediate platelet adherence at normal levels of FVIII-VWF related properties. A recently developed high-purity FVIII-VWF preparation (Concentrate II) containing multimers of high molecular weight normalized the platelet adherence. Platelet adherence in plasma obtained from two patients with von Willebrand’s disease (VWD) was impaired, but plasma samples obtained following treatment with Concentrate II mediated normal platelet adherence. The normalization of platelet adherence paralleled the normalization of the bleeding time.

This platelet adherence assay offers an inexpensive and efficient in vitro tool to test the efficacy of FVIII-VWF preparations designed for VWD patients. Preparations such as cryoprecipitate and Concentrate II mediated the platelet adherence and normalized the bleeding time. The commercial preparation did not mediate platelet adherence and had no effect on the bleeding time.

Keywords

Platelet adherence - Bleeding time - Von Willebrand’s disease - FVIII-von Willebrand factor

PDF (354 kb)

References

References
1 Van Mourik JA, Bouma BN, Labruyére WT, de Graaf S, Mochtar IA. Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 1974; 4: 155-164
2 Zimmerman TS, Roberts J, Edgington TS. Factor VIII related antigen: Multiple molecular forms in plasma. Proc Nat Acad Sci USA 1975; 72: 5121-5125
3 Counts RB, Paskell SL, Elgee SK. Disulfide bonds and the quaternary structure of factor VIII: von Willebrand factor. J Clin Invest 1978; 62: 702-709
4 Van Mourik J, Bolhuis PA. Dispersity of human factor VIII-von Willebrand factor. Thromb Res 1978; 13: 15-24
5 Owen WG, Wagner RH. Antihemophilic factor: Separation of an active fragment following dissociation by salts or detergents. Thrombos Diathes Haemorrh 1972; 27: 502-515
6 Weiss HJ, Phillips LL. Separation of subunits of antihaemophilic factor (AHF) by agarose gel chromatography. Thrombos Diathes Haemorrh 1972; 27: 212-219
7 Bouma BN, Wiegerinck Y, Sixma JJ, van MourikJ, Mochtar IA. Immunological characterization of purified antihemophilic factor A (Factor VIII) which corrects abnormal platelet retention in von Willebrand’s disease. Nature New Biol 1972; 236: 104-106
8 Rick ME, Hoyer LW. Immunologic studies of antihemophilic factor (AHF factor VIII). V. Immunologic properties of AHF subunit produced by salt dissociation. Blood 1973; 42: 737-747
9 Bouma BN, Dodds WJ, van MourikJ, Sixma JJ, Wester WP. Infusion of human and canine factor VIII in dogs with von Willebrand’s disease: Studies of the von Willebrand and factor VIII synthesis stimulating factors. Scand J Haematol 1976; 17: 263-275
10 Patek AJ, Taylor FH C. Hemophilia II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest 1937; 16: 113-124
11 Nilsson IM, Blombäck M, Jorpes E, Blombäck B, Johannsson SA. Von Willebrand’s disease and its correction with human plasma fraction I-O. Acta Med Scand 1957; 159: 179-188
12 Zimmerman TS, Ruggeri ZM. Von Willebrand’s disease. In: Spaet TH. (ed) Progress in Hemostasis and Thrombosis. Grune & Stratton Inc; New York: 1982. 6 203
13 Jørgensen L, Borchgrevink CF. The haemostatic mechanism in patients with haemorrhagic disease. Acta Pathol Microbiol Scand 1964; 60: 55-82
14 Hovig T, Stormorken H. Ultrastructural studies on the platelet formation in bleeding time wounds from normal individuals and patients with von Willebrand’s disease. Acta Pathol Microbiol Scand 1974; 248: 105-122
15 Tschopp TB, Weiss HJ, Baumgartner HR. Decreased adhesion of platelets to subendothelium in von Willebrand’s disease. J Lab Clin Med 1974; 83: 296-300
16 Sakariassen KS, Cattaneo M, Berg Av d, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-236
17 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VHI-von Willebrand factor bound to the subendothelium. Nature 1979; 297: 636-638
18 Cornu P, Larrieu MJ, Caen J, Bernard J. Transfusion studies in von Willebrand’s disease: Effect on bleeding time and factor VIII. Br J Haematol 1963; 9: 189-202
19 Bennet B, Dormandy K. Pool’s cryoprecipitate and exhausted plasma in the treatment of von Willebrand’s disease and factor XI deficiency. Lancet 1966; 2: 731-732
20 Perkins PA. Correction of the hemostatic defects in von Willebrand’s disease. Blood 1967; 30: 375-380
21 Blatt PhM, Brinkhous KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand’s disease. Dissociation of bleeding time factor and ristocetin cofactor activities JAMA 1976; 236: 2770-2772
22 Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrand’s disease. Am J Med 1976; 60: 357-360
23 Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium. Effect of factor VIII-von Willebrand factor of various multimeric composition Blood 1984; 63: 128-139
24 Thorell L, Blombäck M, Blombäck B. An in vivo study of a new factor VIII, high purity, preparation. Thromb Res 1983; 31: 375-385
25 Duke VW. The relation of blood platelets to hemorrhagic disease: Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 1910; 55: 1185-1192
26 Ivy AC, Shapiro PF, Melnick P. The bleeding time in jaundice. Surg Gynecol Obstet 1935; 60: 781-784
27 Van Mourik J, Mochtar IA. Purification of human antihemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta 1970; 221: 677-679
28 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-576
29 Thorell L, Blomback B. Purification of the factor VIII complex. Thromb Res. 1984 (in press)
30 Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders. I. Thrombos Diathes Haemorrh 1968; 19: 279-303
31 Bouma BN, Starkenburg AE. Diluton of haemophilic plasma used as a reagent in the determination of anti-hemophilic factor A (factor VIII). Haemostasis 1974; 3: 94-97
32 Veltkamp JJ, van TilburgN H. Detection of heterozygotes of recessive von Willebrand’s disease by the assay of antihemophilic- factor-like antigen. N Engl J Med 1973; 289: 882-885
33 MacFarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin factor). Thrombos Diathes Haemorrh 1975; 34: 306-308
34 Over JN, Bouma BN, van MourikJ, Sixma JJ, Vlooswijk RA, Bakker-Woudenberg IHeterogeneity. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med 1978; 91: 32-46
35 Aarts PA M M, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ. Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood 1983; 62: 214-217
36 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179
37 Sakariassen KS, Bolhuis PA, Sixma JJ. Platelet adherence to subendothelium of human arteries in pulsatile and steady flow. Thromb Res 1980; 415: 547-559
38 Sakariassen KS, Ottenhof-Rovers H, Sixma JJ. Factor VIII-von Willebrand factor requires calcium for facilitation of platelet adherence. Blood 1984; 63: 996-1003
39 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear-dependent decrease of adherence in von Willebrand’s disease and the Bemard-Soulier syndrome. J Lab Clin Med 1978; 92: 750-764